Antiphospholipid syndrome (APS) is an autoimmune disorder associated with either arterial and/or venous thrombosis (1). Two cases of APS, which were diagnosed in the second trimester during the diagnostic workup of fetal bradycardia, are presented. . 2. Lupus anticoagulant present in plasma, on 2 or more occasions at least 6 weeks apart, detected according to the guidelines of the International Society on Thrombosis and Hemostasis (Scientific Subcommittee on Lupus Anticoagulants/Phospholipid-Dependent Antibodies), in the following steps: 2. (a) Prolonged phospholipid-dependent coagulation demonstrated on a screening test, e.g., activated partial thromboplastin time, kaolin clotting time, dilute Russell's viper venom time, dilute prothrombin time, Textarin time. 2. (b) Failure to correct the prolonged coagulation time on the screening test by mixing with normal platelet-poor plasma.
Mothers who have autoimmune diseases are at risk of delivering an affected infant with inborn defects such as congenital complete heart block (CCHB), and structural cardiac malformations (2) . Fetal bradycardia appearing in the second trimester may be an indicator of antiphospholipid syndrome/circulating anticoagulants in maternal serum and deserves fetal-maternal investigation (including antiphospholipid antibodies), close monitoring, and treatment.
CASE 1
A 20-year-old woman, gravida 2 para 0 abortus 1, was admitted to our outpatient clinic on 11th week of gestation for routine control. Her medical history and physical examination were unremarkable. The pregnancy continued un-eventfully until the 22nd week of gestation, when external fetal monitoring showed fetal bradycardia. Detailed fetal echocardiography showed no cardiac structural defect nor evidence of heart failure but revealed fetal sinus bradycardia, 20 to 30 beats per 1 minute.
Despite the fact that the patient had no symptoms related to systemic lupus erythematosus, fetal bradycardia and a history of miscarriage were suggestive of circulating anticoagulants in maternal serum.
Laboratory findings were as follows: hemoglobin 12.5 g/dL, hematocrit 35.1 mL/dL, platelet count 227 × 10 9 /L, white blood cell count 11.0 × 10 9 /L. The immunofluorescence method was used to detect antinuclear antibody (ANA), which was positive (homogeneous pattern). Enzyme immunoassay method indicated anticardiolipin antibody (ACA) IgG: 11 U/mL (normal, 0-10 U/mL), anticardiolipin antibody (ACA) IgM: 22 U/mL (normal, 0-14 U/mL), Lupus anticoagulants were negative.
According to the recommendations of the hematologist, acetylsalicylic acid 80 mg/day and low-molecular-weight heparin (Nadroparine calcium, 175 anti-Xa U/kg per day) were commenced. On the 24th and 28th weeks of pregnancy, although the ultrasonogpaphic examinations revealed 2 weeks restriction, there was lin-ear fetal growth. Doppler ultrasound examination showed no pathology of fetal blood flow. The amniotic fluid volume was normal until 34 weeks of gestation. Acetylsalicylic acid was stopped at 34 weeks of gestation. On the ultrasonographic control at the 35th week of gestation, fetal biometry corresponded with 31 weeks of gestation, and the four-quadrant amniotic index was 60 mm. Doppler ultrasound examination was normal. Fetal cardiotocography was reactive and showed minimal contractions. At 35 weeks 5 days, the patient gave birth via caesarean section to a healthy female infant that weighed 2030 g and was 43 cm long. Her apgar scores were 9 and 10 at 1 and 5 minutes, respectively.
CASE 2
A 25-year-old primigravida woman presented to our outpatient clinic on the 6th week of her pregnancy. She was on thyroxine sodium 0.1 mg/day therapy for hypothyroidism. Her physical examination was unremarkable. The progression of pregnancy was uneventfull, until the 22nd week of gestation, when external fetal monitoring revealed fetal bradycardia. Fetal echocardiography showed no problem.
Laboratory findings were as follows: hemoglobin 13.3 g/dL, hematocrit 39.1 mL/dL, platelet count 282 × 10 9 /L, white blood cell count 7.7 × 10 9 /L, positive ANA (homogeneous pattern), ACA IgG 1.0 U/mL, ACA IgM 4.0 U/mL, negative lupus anticoagulants.
The patient was given acetylsalicylic acid 80 mg/day and Nadroparine calcium 175 anti-Xa U/kg per day until 35 weeks of gestation. At 31 weeks of gestation, she was hospitalized for preterm labor, which was stopped with hydration and sedation. On the ultrasonographic control fetal biometry showed a linear growth with no pathology of fetal blood flow. At 37 weeks of Definite antiphospholipid antibody syndrome is considered to be present if at least one of the clinical criteria and one of the laboratory criteria are met.
Clinical criteria

Vascular thrombosis
One or more clinical episodes of arterial, venous, or small vessel thrombosis in any tissue or organ. Thrombosis must be confirmed by imaging or Doppler studies or histopathology, with the exception of superficial venous thrombosis. For histopathologic confirmation, thrombosis should be present without significant inflammation in the vessel wall.
2. Pregnancy morbidity (a) One or more unexplained deaths of a morphologically normal fetus at or beyond the 10th week of gestation, with normal fetal morphology documented by ultrasound or by direct examination of the fetus, or 2. (b) One or more premature births of a morphologically normal neonate at or before the 34th week of gestation because of severe preeclampsia or eclampsia, or severe placental insufficiency, or 2. (c) Three or more unexplained consecutive spontaneous abortions before the 10th week of gestation, with maternal anatomic or hormonal abnormalities and paternal and maternal chromosal causes excluded.
2. In studies of populations of patients who have more than 1 type of pregnancy morbidity, investigators are strongly encouraged to stratify groups of subjects according to a, b, or c above.
Laboratory criteria
1. Anticardiolipin antibody of IgG and/or IgM isotype in blood, present in medium or high titer, on two or more occasions, at least 6 weeks apart, measured by a standardized enzyme-linked immunosorbent assay for beta 2 -glycoprotein I-dependent anticardiolipin antibodies. gestation, fetal cardiotocography was nonreactive and showed regular contractions. On the same day she gave birth with caesarean section to a healthy male infant that weighed 3230 g and was 50 cm long.
DISCUSSION
Antiphospholipid antibodies are a group of autoantibodies that exhibit a broad range of target specificities and affinities, all recognizing various combination of phospholipids, phospholipidbinding proteins, or both. The term 'antiphospholipid syndrome' was first used to denote the clinical association between antiphospholipid antibodies and a syndrome of hypercoagulability (1, 3) . International consensus statement on preliminary criteria for the classification of the antiphospholipid syndrome is shown in Table 1 (4) .
Women with this syndrome have an unusually high rate of pregnancy complications such as pregnancy losses, premature delivery due to pregnancy-asssociated hypertensive disease, and uteroplacental insufficiency (1) . The prevalance of CCHB in newborns of women already known to be antiphospholipid antibodies positive is 2% (2) . Therefore, mothers with antiphospholipid syndrome must be closely monitored throughout their pregnancies.
Adverse pregnancy outcomes in women with the antiphospholipid syndrome may result from poor placental perfusion due to localized thrombosis. Antiphospholipid antibodies may also impair trophoblastic invasion and hormone production, thereby promoting not only pre-embryonic and embryonic loss but also fetal loss and uteroplacental insufficiency (1) . The available case reports (5, 6) in the literature presents the complications in pregnant patients already known to have antiphospholipid antibodies and to our knowledge there are no articles about the patients with antiphospholipid syndrome during the diagnostic workup of fetal bradycardia. We report two patients who were healthy until the second trimester of their pregnancies, but were diagnosed as having antiphospholipid syndrome because of fetal bradycardia.
To conclude, second-trimester fetal bradycardia may be an indicator of antiphospholipid syndrome/circulating anticoagulants in maternal serum and deserves fetal-maternal investigations and close monitoring and treatment if antiphospholipid antibodies are positive.
